Endurobol

Endurobol, also known as GW-501516 or Cardarine, is a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It was originally developed by GlaxoSmithKline and Ligand Pharmaceuticals in the 1990s for the treatment of metabolic and cardiovascular diseases. Research indicated that Endurobol could potentially increase endurance, fat metabolism, and levels of high-density lipoprotein cholesterol.

Studies on animals showed promising results in improving lipid profiles and enhancing exercise capacity. However, significant concerns arose regarding its safety. In preclinical trials involving rodents, high doses of Endurobol were linked to the development of various cancers, including liver, stomach, skin, and breast cancers. These findings led to the termination of its clinical development for human use by GlaxoSmithKline.

Despite the cessation of pharmaceutical development, Endurobol gained popularity in the bodybuilding and athletic communities as a performance-enhancing substance. Users often report increased endurance, faster recovery times, and enhanced fat loss. It is frequently purchased online from suppliers of research chemicals.

The regulatory status of Endurobol varies globally. It is not approved for human consumption by regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The World Anti-Doping Agency (WADA) lists Endurobol as a prohibited substance in sports. Due to the lack of approved human trials and the documented carcinogenic risks observed in animal studies, its use is considered unsafe and is strongly discouraged by medical professionals.